Valeo Pharma Inc.

OTCPK:VPHI.F Stock Report

Market Cap: US$4.6m

Valeo Pharma Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Al Moghaddam

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.6yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

CEO

Al Moghaddam (57 yo)

less than a year

Tenure

Mr. Al Moghaddam, B. Com. CMA had been a Director at Valeo Pharma Inc. since March 21, 2024 until June 2024 and served as its Chief Development Officer since June 2024 until August 2024 and serves as its C...

Leadership Team

NamePositionTenureCompensationOwnership
Kyle Steiger
Senior VP & Chief Commercial Officer2.3yrsCA$388.21k0.020%
$ 909.4
Al Moghaddam
Chief Executive Officerless than a yearno datano data
Pascal Tougas
Chief Financial Officerless than a yearno datano data
Frédéric Dumais
Director of Communications & Investor Relationsno datano data0.26%
$ 12.1k
Guy-Paul Allard
VP of Legal Affairs & Corporate Secretaryno datano data0%
$ 0
Jean Fournier
Head of Ophthalmology Business Unit2.3yrsno datano data

1.6yrs

Average Tenure

Experienced Management: VPHI.F's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Robert Raich
Independent Directorless than a yearno data0.18%
$ 8.2k
Richard MacKay
Chairman of the Advisory Board & Director15.8yrsno data16.44%
$ 760.8k
Steven Saviuk
Chairman21.7yrsCA$466.29k0.18%
$ 8.5k
Marc Leger
Independent Non-Executive Director2.6yrsno data2.36%
$ 109.3k
Richard Lajoie
Independent Directorless than a yearno datano data
Charles Bisaillon
Independent Directorless than a yearno datano data

1.8yrs

Average Tenure

65yo

Average Age

Experienced Board: VPHI.F's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.